Amicus Therapeutics Inc. (FOLD) and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) Contrasting side by side

Amicus Therapeutics Inc. (NASDAQ:FOLD) and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA), both competing one another are Biotechnology companies. We will contrast their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Amicus Therapeutics Inc. 12 19.07 N/A -2.15 0.00
Dicerna Pharmaceuticals Inc. 13 73.51 N/A -1.70 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.


Table 2 has Amicus Therapeutics Inc. and Dicerna Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Amicus Therapeutics Inc. 0.00% -94.9% -52.1%
Dicerna Pharmaceuticals Inc. 0.00% -66.1% -37.2%

Risk & Volatility

Amicus Therapeutics Inc. has a 1.83 beta, while its volatility is 83.00%, thus making it more volatile than Standard & Poor’s 500. In other hand, Dicerna Pharmaceuticals Inc. has beta of 2.14 which is 114.00% more volatile than Standard & Poor’s 500.


Amicus Therapeutics Inc. has a Current Ratio of 7.3 and a Quick Ratio of 7.2. Competitively, Dicerna Pharmaceuticals Inc.’s Current Ratio is 5 and has 5 Quick Ratio. Amicus Therapeutics Inc.’s better ability to pay short and long-term obligations than Dicerna Pharmaceuticals Inc.

Analyst Ratings

Recommendations and Ratings for Amicus Therapeutics Inc. and Dicerna Pharmaceuticals Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Amicus Therapeutics Inc. 0 0 1 3.00
Dicerna Pharmaceuticals Inc. 0 0 5 3.00

Amicus Therapeutics Inc.’s upside potential currently stands at 103.25% and an $20 average target price. Dicerna Pharmaceuticals Inc. on the other hand boasts of a $23.6 average target price and a 84.81% potential upside. Based on the results delivered earlier, Amicus Therapeutics Inc. is looking more favorable than Dicerna Pharmaceuticals Inc., analysts view.

Insider & Institutional Ownership

The shares of both Amicus Therapeutics Inc. and Dicerna Pharmaceuticals Inc. are owned by institutional investors at 0% and 90% respectively. Insiders owned 0.9% of Amicus Therapeutics Inc. shares. On the other hand, insiders owned about 8.38% of Dicerna Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Amicus Therapeutics Inc. -1.9% -0.4% -7.53% 6.26% -13.23% 29.44%
Dicerna Pharmaceuticals Inc. -10.03% -12.68% 8.52% 35.62% 9.57% 27.5%

For the past year Amicus Therapeutics Inc.’s stock price has bigger growth than Dicerna Pharmaceuticals Inc.


On 5 of the 8 factors Dicerna Pharmaceuticals Inc. beats Amicus Therapeutics Inc.

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.